JPMorgan raised the firm’s price target on CME Group (CME) to $266 from $262 and keeps an Underweight rating on the shares. The company’s Q4 results were largely inline, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $328 from $305 at TD Cowen
- CME Group price target raised to $340 from $319 at Morgan Stanley
- CME Group: Resilient Fee-Based Franchise with Defensive Strengths and Underappreciated Structural Growth Justifies Buy Rating
- CME Group price target raised to $312 from $304 at Barclays
- CME Group reports Q4 adjusted EPS $2.77, consensus $2.74